Executive appointments at SOTIO Bio

SOTIO Biotech, a Czech biopharma owned by PPF Group, today announced the appointments of two accomplished scientific executives to its leadership team to support the continued progress of SOTIO’s pipeline of novel antibody-drug conjugates and immunotherapies for difficult-to-treat solid tumors.

Amy Jensen-Smith has been named SOTIO’s chief scientific officer, in which capacity she will oversee platform expansion and discovery research; Ulrich Moebius, as chief development officer, will direct the company’s translational research and drug development strategy.

“We are fortunate to have such exceptional scientific talent within SOTIO to lead the continued progress and expansion of our portfolio of next-generation ADCs and immunotherapies,” said Radek Spisek, chief executive of SOTIO, adding: “Amy's proven record of scientific excellence and innovation as vice president has been instrumental in advancing our pipeline and guiding our scientific strategy. Ulrich has long been at the center of our development strategy, and his leadership of our preclinical organization makes him uniquely qualified to serve as chief development officer.”